CoChat
Sign Up
Cited by 56

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Brain regional correlation of amyloid-β with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-β accumulation

Shinohara, Mitsuru, Petersen, Ronald C., Dickson, Dennis W., Bu, Guojun·2013·Acta Neuropathologica
DOI 10.1007/s00401-013-1086-9PMC PMC3612369
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-013-1086-9

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 19 references

Research works printed but not linked: 52

  1. Akiyama H, Kondo H, Ikeda K, Kato M, McGeer PL (2001) Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid beta-protein (Abeta) deposition. Brain Res 902:277–281 · DOI
  2. Arold S, Sullivan P, Bilousova T et al (2012) Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer’s disease and apoE TR mouse cortex. Acta Neuropathol 123:39–52 · DOI
  3. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer’s disease. Lancet 377:1019–1031. doi: 10.1016/s0140-6736(10)61349-9 · DOI · Paper page
  4. Benkovic SA, McGowan EM, Rothwell NJ, Hutton M, Morgan DG, Gordon MN (1997) Regional and cellular localization of presenilin-2 RNA in rat and human brain. Exp Neurol 145:555–564. doi: 10.1006/exnr.1997.6487 · DOI
  5. Bernstein HG, Ansorge S, Riederer P, Reiser M, Frolich L, Bogerts B (1999) Insulin-degrading enzyme in the Alzheimer’s disease brain: prominent localization in neurons and senile plaques. Neurosci Lett 263:161–164 · DOI
  6. Bero AW, Yan P, Roh JH et al (2011) Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci 14:750–756. doi: 10.1038/nn.2801 · DOI · Paper page
  7. Bramanti V, Tomassoni D, Avitabile M, Amenta F, Avola R (2010) Biomarkers of glial cell proliferation and differentiation in culture. Front Biosci 2:558–570 · DOI
  8. Camus MC, Chapman MJ, Forgez P, Laplaud PM (1983) Distribution and characterization of the serum lipoproteins and apoproteins in the mouse, Mus musculus. J Lipid Res 24:1210–1228 · DOI
  9. Chakrabarty P, Jansen-West K, Beccard A et al (2010) Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J 24:548–559. doi: 10.1096/fj.09-141754 · DOI · Paper page
  10. Cirrito JR, Yamada KA, Finn MB et al (2005) Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48:913–922. doi: 10.1016/j.neuron.2005.10.028 · DOI · Paper page
  11. De Strooper B, Vassar R, Golde T (2010) The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 6:99–107 · DOI · Paper page
  12. Delledonne A, Kouri N, Reinstatler L et al (2009) Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme. Mol Neurodegener 4:39. doi: 10.1186/1750-1326-4-39 · DOI
  13. Dickson DW, Crystal HA, Mattiace LA et al (1992) Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 13:179–189 · DOI · Paper page
  14. Goedert M (1987) Neuronal localization of amyloid beta protein precursor mRNA in normal human brain and in Alzheimer’s disease. EMBO J 6:3627–3632 · DOI
  15. Goulinet S, Chapman MJ (1993) Plasma lipoproteins in the golden Syrian hamster (Mesocricetus auratus): heterogeneity of apoB- and apoA-I-containing particles. J Lipid Res 34:943–959 · DOI
  16. Gupta VB, Laws SM, Villemagne VL et al (2011) Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 76:1091–1098 · DOI · Paper page
  17. Haddy N, De Bacquer D, Chemaly MM et al (2002) The importance of plasma apolipoprotein E concentration in addition to its common polymorphism on inter-individual variation in lipid levels: results from Apo Europe. Eur J Hum Genet 10:841–850 · DOI · Paper page
  18. Holtzman DM, Fagan AM, Mackey B et al (2000) Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer’s disease model. Ann Neurol 47:739–747 · DOI
  19. Iwata N, Tsubuki S, Takaki Y et al (2001) Metabolic regulation of brain Abeta by neprilysin. Science 292:1550–1552. doi: 10.1126/science.1059946 · DOI
  20. Jack CR Jr, Knopman DS, Jagust WJ et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9:119–128. doi: 10.1016/s1474-4422(09)70299-6 · DOI · Paper page
  21. Jack CR Jr, Lowe VJ, Weigand SD et al (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 132:1355–1365. doi: 10.1093/brain/awp062 · DOI · Paper page
  22. Jack CR Jr, Wiste HJ, Vemuri P et al (2010) Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease. Brain 133:3336–3348 · DOI · Paper page
  23. Kanekiyo T, Liu CC, Shinohara M, Li J, Bu G (2012) LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer’s amyloid-beta. J Neurosci 32:16458–16465. doi: 10.1523/jneurosci.3987-12.2012 · DOI · Paper page
  24. Klunk WE, Price JC, Mathis CA et al (2007) Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27:6174–6184. doi: 10.1523/jneurosci.0730-07.2007 · DOI · Paper page
  25. Koffie R, Hyman B, Spires-Jones T (2011) Alzheimer’s disease: synapses gone cold. Molecular Neurodegeneration 6:63 · DOI
  26. Koffie RM, Meyer-Luehmann M, Hashimoto T et al (2009) Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 106:4012–4017. doi: 10.1073/pnas.0811698106 · DOI · Paper page
  27. Lazarov O, Lee M, Peterson DA, Sisodia SS (2002) Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci 22:9785–9793 · DOI · Paper page
  28. Leissring MA, Farris W, Chang AY et al (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40:1087–1093 · DOI
  29. Marquez-Sterling NR, Lo AC, Sisodia SS, Koo EH (1997) Trafficking of cell-surface beta-amyloid precursor protein: evidence that a sorting intermediate participates in synaptic vesicle recycling. J Neurosci 17:140–151 · DOI
  30. May P, Rohlmann A, Bock HH et al (2004) Neuronal LRP1 functionally associates with postsynaptic proteins and is required for normal motor function in mice. Mol Cell Biol 24:8872–8883. doi: 10.1128/mcb.24.20.8872-8883.2004 · DOI · Paper page
  31. Meilandt WJ, Cisse M, Ho K et al (2009) Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci 29:1977–1986. doi: 10.1523/jneurosci.2984-08.2009 · DOI
  32. Miller BC, Eckman EA, Sambamurti K et al (2003) Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci USA 100:6221–6226. doi: 10.1073/pnas.1031520100 · DOI · Paper page
  33. Moore AH, O’Banion MK (2002) Neuroinflammation and anti-inflammatory therapy for Alzheimer’s disease. Adv Drug Deliv Rev 54:1627–1656 · DOI
  34. Moore BD, Chakrabarty P, Levites Y et al (2012) Overlapping profiles of Abeta peptides in the Alzheimer’s disease and pathological aging brains. Alzheimers Res Ther 4(3):18 · DOI
  35. Nalivaeva NN, Beckett C, Belyaev ND, Turner AJ (2012) Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease? J Neurochem 1:167–185 · DOI · Paper page
  36. Okello A, Koivunen J, Edison P et al (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73:754–760 · DOI
  37. Page K, Hollister R, Tanzi RE, Hyman BT (1996) In situ hybridization analysis of presenilin 1 mRNA in Alzheimer disease and in lesioned rat brain. Proc Natl Acad Sci USA 93:14020–14024 · DOI
  38. Pocivavsek A, Burns MP, Rebeck GW (2009) Low-density lipoprotein receptors regulate microglial inflammation through c-Jun N-terminal kinase. Glia 57:444–453. doi: 10.1002/glia.20772 · DOI · Paper page
  39. Shankar GM, Li S, Mehta TH et al (2008) Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 14:837–842. doi: 10.1038/nm1782 · DOI · Paper page
  40. Shigematsu K, McGeer PL, McGeer EG (1992) Localization of amyloid precursor protein in selective postsynaptic densities of rat cortical neurons. Brain Res 592:353–357 · DOI · Paper page
  41. Sokolow S, Luu SH, Nandy K et al (2012) Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer’s disease cortex. Neurobiol Dis 45:381–387 · DOI
  42. Suh J, Lyckman A, Wang L, Eckman EA, Guenette SY (2011) FE65 proteins regulate NMDA receptor activation-induced amyloid precursor protein processing. J Neurochem 119:377–388 · DOI
  43. Sullivan PM, Han B, Liu F et al (2011) Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol Aging 32:791–801 · DOI · Paper page
  44. Takahashi RH, Milner TA, Li F et al (2002) Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161:1869–1879 · DOI · Paper page
  45. Takami K, Terai K, Matsuo A, Walker DG, McGeer PL (1997) Expression of presenilin-1 and -2 mRNAs in rat and Alzheimer’s disease brains. Brain Res 748:122–130 · DOI
  46. Thal DR (2012) The role of astrocytes in amyloid beta-protein toxicity and clearance. Exp Neurol 236:1–5 · DOI
  47. Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800 · DOI · Paper page
  48. Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283:29615–29619. doi: 10.1074/jbc.R800019200 · DOI · Paper page
  49. Vassar R, Bennett BD, Babu-Khan S et al (1999) Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735–741 · DOI · Paper page
  50. Verges DK, Restivo JL, Goebel WD, Holtzman DM, Cirrito JR (2011) Opposing synaptic regulation of amyloid-beta metabolism by NMDA receptors in vivo. J Neurosci 31:11328–11337 · DOI · Paper page
  51. Villemagne VL, Ataka S, Mizuno T et al (2009) High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol 66:1537–1544. doi: 10.1001/archneurol.2009.285 · DOI
  52. Wenk GL (2003) Neuropathologic changes in Alzheimer’s disease. J Clin Psychiatry 9:7–10

Cited by

Sorted by citations

See all 56

Metadata

Authors
Shinohara, M., Petersen, R. C., Dickson, D. W., & Bu, G.
Venue
Acta Neuropathologica
Publisher
Springer Science and Business Media LLC
Published
2013-01-31
Volume
125
Issue
4
Pages
535-547
ISSN
  • 0001-6322
  • 1432-0533
DOI
10.1007/s00401-013-1086-9
PMC
PMC3612369
Cited by
56
References
19
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review